Rectum Cancer Clinical Trial
Official title:
End to End Versus Side to End Anastomosis After Anterior Resection of Cancer Rectum
Comparison between end to end and side to end anastomosis after anterior resection of cancer rectum and compare the outcomes of both surgical techniques. The main outcomes were bowel functional outcomes and QoL. Bowel functional outcomes mainly included three indexes: stool frequency, urgency, incomplete defecation, and incontinence. The secondary outcomes were surgical outcomes including operative time, postoperative hospital stay, postoperative complications, reoperation, and mortality.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | March 20, 2025 |
Est. primary completion date | January 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - 18 years of age to 80 years. - Laparoscopic or open anterior resection of cancer rectum. Exclusion Criteria: - synchronous colorectal carcinoma - emergency surgery - history of colon or rectal segmental resections - fixed rectal carcinoma who received preoperative radiotherapy |
Country | Name | City | State |
---|---|---|---|
Egypt | Sohag university | Sohag |
Lead Sponsor | Collaborator |
---|---|
Sohag University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Operative time | in minutes | Immediate postoperative | |
Primary | Anastomotic leakage | yes or No | 2 weeks postoperative | |
Primary | hospital stay | in days | 2 weeks postoperative | |
Primary | Mortality | yes or no | 4 weeks postoperative | |
Primary | Anastomotic leak amount | in cubic centimeters | 2 weeks postoperative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Completed |
NCT00409994 -
Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04371198 -
Patient-Derived Organoids for Rectal Cancer
|
N/A | |
Recruiting |
NCT04916990 -
Improving Care for Rural Patients With Solid Tumors
|
N/A | |
Active, not recruiting |
NCT05305820 -
Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy
|
N/A | |
Recruiting |
NCT03699761 -
The Role of Pelvic Peritonization in Laparoscopic or Robotic Low Anterior Resection
|
N/A | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT03843957 -
Effectiveness and Implementation of mPATH-CRC
|
N/A | |
Completed |
NCT02423226 -
Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer
|
Phase 2 | |
Completed |
NCT00379743 -
Partnership for Healthy Seniors
|
N/A | |
Completed |
NCT00509444 -
Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
|
Phase 3 | |
Recruiting |
NCT06116019 -
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
|
||
Not yet recruiting |
NCT06066931 -
Reconstruction of the Pelvic Floor and Perineal Wound After Rectal ELAPE
|
N/A | |
Recruiting |
NCT02738359 -
Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening
|
||
Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
Active, not recruiting |
NCT02458664 -
BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer
|
N/A | |
Withdrawn |
NCT03257332 -
Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.
|
||
Recruiting |
NCT05715255 -
Adaptive Symptom Self-Management Immunotherapy Study
|
N/A | |
Completed |
NCT02641691 -
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
|
Phase 2 | |
Recruiting |
NCT04405206 -
Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer
|